Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Orchestra BioMed Holdings Inc. (OBIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: OBIO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $13.57
1 Year Target Price $13.57
| 4 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -72.51% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 143.51M USD | Price to earnings Ratio - | 1Y Target Price 13.57 |
Price to earnings Ratio - | 1Y Target Price 13.57 | ||
Volume (30-day avg) 7 | Beta 0.61 | 52 Weeks Range 2.37 - 7.04 | Updated Date 08/15/2025 |
52 Weeks Range 2.37 - 7.04 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.83 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.5072 | Actual -0.5 |
Profitability
Profit Margin - | Operating Margin (TTM) -2311.84% |
Management Effectiveness
Return on Assets (TTM) -77.32% | Return on Equity (TTM) -313.82% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 125944442 | Price to Sales(TTM) 48.75 |
Enterprise Value 125944442 | Price to Sales(TTM) 48.75 | ||
Enterprise Value to Revenue 42.78 | Enterprise Value to EBITDA -1.81 | Shares Outstanding 53952800 | Shares Floating 32020724 |
Shares Outstanding 53952800 | Shares Floating 32020724 | ||
Percent Insiders 16.19 | Percent Institutions 33.44 |
Upturn AI SWOT
Orchestra BioMed Holdings Inc.
Company Overview
History and Background
Orchestra BioMed Holdings Inc. is a biomedical innovation company focused on developing transformative therapies for cardiovascular diseases. The company was founded in 2009 and went public through a special purpose acquisition company (SPAC) merger in 2023. The company is focused on creating innovative medical devices.
Core Business Areas
- Virtuoso SEB (Sustained Engraftment Bioabsorbable) Coronary Sirolimus Eluting Balloon (SEB): A drug-eluting balloon designed to promote sustained vessel healing after angioplasty.
- Moderato Implantable Pulse Generator (IPG): A neurostimulation device for treating hypertension. It stimulates the vagus nerve to lower blood pressure.
Leadership and Structure
The company is led by David Hochman (Chairman and CEO) and has a management team with experience in medical device development and commercialization. The organizational structure is typical of a biotech company, with departments focused on research and development, clinical trials, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- Virtuoso SEB (Sustained Engraftment Bioabsorbable) Coronary Sirolimus Eluting Balloon (SEB): Virtuoso SEB is Orchestra BioMed's lead product candidate, designed to provide a more sustained and effective treatment for coronary artery disease. Market share is still developing as it awaits regulatory approvals. Competitors include drug-eluting stents from companies like Medtronic (MDT), Abbott (ABT), and Boston Scientific (BSX).
- Moderato Implantable Pulse Generator (IPG): Moderato is a neurostimulation device for treating hypertension. Market share is yet to be established upon regulatory approval. Competitors include companies developing similar neurostimulation therapies, such as CVRx and Medtronic (MDT).
Market Dynamics
Industry Overview
The cardiovascular device market is large and growing, driven by an aging population and increasing prevalence of cardiovascular disease. The market is competitive, with established players and emerging companies developing innovative technologies.
Positioning
Orchestra BioMed is positioned as an innovator in the cardiovascular device space, focusing on developing therapies that address unmet needs and improve patient outcomes. Its competitive advantage lies in its proprietary technology platforms and focus on sustained therapeutic effects.
Total Addressable Market (TAM)
The total addressable market for cardiovascular devices is estimated to be in the tens of billions of dollars. Orchestra BioMed is targeting specific segments of this market with its Virtuoso SEB and Moderato IPG, and its positioning allows it to capture a share of this market.
Upturn SWOT Analysis
Strengths
- Innovative technology platforms
- Strong intellectual property portfolio
- Experienced management team
- Focus on unmet needs in cardiovascular disease
Weaknesses
- Reliance on regulatory approvals
- Limited commercialization experience
- Dependence on key partnerships
- Cash burn rate
Opportunities
- Expanding applications of Virtuoso SEB
- Partnerships with larger medical device companies
- Geographic expansion
- Positive clinical trial results
Threats
- Competition from established players
- Regulatory setbacks
- Technological obsolescence
- Economic downturn
Competitors and Market Share
Key Competitors
- MDT
- ABT
- BSX
- CVRX
Competitive Landscape
Orchestra BioMed faces intense competition from established medical device companies. Its advantages include its innovative technology platforms and focus on sustained therapeutic effects. Its disadvantages include its limited commercialization experience and dependence on regulatory approvals.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is not applicable as Orchestra BioMed only recently became public.
Future Projections: Future growth is projected to be driven by the regulatory approvals and commercialization of Virtuoso SEB and Moderato IPG. Analyst estimates vary depending on the success of clinical trials and market adoption.
Recent Initiatives: Recent initiatives include completing clinical trials for Virtuoso SEB and Moderato IPG, securing regulatory approvals, and establishing strategic partnerships.
Summary
Orchestra BioMed is a high-risk, high-reward biomedical company poised to disrupt the cardiovascular device market with its innovative therapies. Its success hinges on obtaining regulatory approvals, successful clinical trials, and market acceptance. The company's lack of revenue and reliance on future funding pose significant risks. The company needs to be careful about their Cash Burn Rate to ensure that they have enough money to bring the product through the FDA approval pipeline.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investing in biotechnology companies is highly speculative and involves significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Orchestra BioMed Holdings Inc.
Exchange NASDAQ | Headquaters New Hope, PA, United States | ||
IPO Launch date 2020-08-04 | Founder, Chairman of the Board of Directors & CEO Mr. David P. Hochman | ||
Sector Healthcare | Industry Biotechnology | Full time employees 70 | Website https://orchestrabiomed.com |
Full time employees 70 | Website https://orchestrabiomed.com | ||
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure. In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures. It has a collaboration agreement with Medtronic, Inc. for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.